Submit Covaxin Phase 3 efficacy data before seeking nod for kids trials: SEC

Submit Covaxin Phase 3 efficacy data before seeking nod for kids trials: SEC The Subject Expert Committee (SEC), which advises the Indian drug regulator Drugs Controller General of India (DCGI), has asked Bharat Biotech to submit efficacy and safety data from its ongoing Phase III Covaxin trials before seeking approval for conducting trials on children. https://ift.tt/eA8V8J